Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.

The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.
Stomach Cancer|Gastro Esophageal Junction Cancer
DRUG: Atezolizumab|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Docetaxel
Incidence of adverse events following treatment (safety), Adverse events will be assessed (according to CTC-AE v4.0) during treatment, until 100 days after last patient last study drug treatment
pathological tumor regression grade, determined using the Mandard tumor regression grading system, Within 6 months after last patient inclusion
In this single-centre, open-label, monocenter study, the investigators will enroll 20 patients with resectable cancer of the stomach of GEJunction.

All patients will be treated with 1 cycle of atezolizumab monotherapy, followed by 4 cycles of combinationtherapy of atezolizumab, capecitabine, oxaliplatin and docetaxel, followed by surgery.